This project enables the mapping of the immune response by determining the patient-specific "omics" immunome, and to establish biomarkers for the early detection of severe disease progressions, in order to be able to intervene therapeutically before ventilation is required. New therapeutic starting points can be identified and, if necessary, favorably influenced with known drugs. Patients with defective immune system reconstitution are detected at an early stage in order to achieve a restoration of the immune system after a SARS-CoV-2 infection with targeted therapies and to prevent or attenuate secondary diseases.
The valid monitoring of a dysregulated immune reaction and the proof of its importance for clinical success makes biomarkers for prognosis and therapy control available for the first time. Since patient selection using biomarkers increases the probability of success of a clinical study with a drug by up to 30%, companies with already approved substances already choose Fraunhofer ITMP as a partner to conduct studies in severe infections.